Kerkhof Marjon, Kusters Johannes G, van Dekken Herman, Kuipers Ernst J, Siersema Peter D
Department of Gastroenterology and Hepatology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.
Cell Oncol. 2007;29(6):507-17. doi: 10.1155/2007/814950.
Barrett esophagus (BE) is caused by chronic gastroesophageal reflux and predisposes to the development of esophageal adenocarcinoma through different grades of dysplasia. Only a subset of BE patients will finally develop esophageal adenocarcinoma. The majority will therefore not benefit from an endoscopic surveillance program, based on the histological identification of dysplasia. Several studies have been performed to find additional biomarkers that can be used to detect the subgroup of patients with an increased risk of developing malignancy in BE. In this review, we will summarize the most promising tissue biomarkers, i.e. proliferation/cell cycle proteins, tumor suppressor genes, adhesion molecules, DNA ploidy status and inflammation associated markers, that can be used for risk stratification in BE, and discuss their respective clinical application.
巴雷特食管（BE）由慢性胃食管反流引起，并通过不同程度的发育异常易引发食管腺癌。只有一部分BE患者最终会发展为食管腺癌。因此，基于发育异常的组织学鉴定，大多数患者无法从内镜监测计划中获益。已经开展了多项研究以寻找额外的生物标志物，用于检测BE中发生恶性肿瘤风险增加的患者亚组。在本综述中，我们将总结最有前景的组织生物标志物，即增殖/细胞周期蛋白、肿瘤抑制基因、黏附分子、DNA倍体状态和炎症相关标志物，这些标志物可用于BE的风险分层，并讨论它们各自的临床应用。
